187 related articles for article (PubMed ID: 28816165)
1. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Ning MS; Tang L; Gomez DR; Xu T; Luo Y; Huo J; Mouhayar E; Liao Z
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):70-79. PubMed ID: 28816165
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
3. Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer.
Cella L; Monti S; Xu T; Liuzzi R; Stanzione A; Durante M; Mohan R; Liao Z; Palma G
Radiother Oncol; 2021 Jul; 160():148-158. PubMed ID: 33979653
[TBL] [Abstract][Full Text] [Related]
4. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
5. Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.
Xue J; Han C; Jackson A; Hu C; Yao H; Wang W; Hayman J; Chen W; Jin J; Kalemkerian GP; Matuzsak M; Jolly S; Kong FS
Radiother Oncol; 2019 Apr; 133():213-219. PubMed ID: 30416046
[TBL] [Abstract][Full Text] [Related]
6. Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer.
Pao TH; Chang WL; Chiang NJ; Lin CY; Lai WW; Tseng YL; Lin FC
Radiat Oncol; 2020 Feb; 15(1):48. PubMed ID: 32103779
[TBL] [Abstract][Full Text] [Related]
7. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
8. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
[TBL] [Abstract][Full Text] [Related]
9. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
10. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
[TBL] [Abstract][Full Text] [Related]
11. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy.
Chen C; Uyterlinde W; Sonke JJ; de Bois J; van den Heuvel M; Belderbos J
Radiother Oncol; 2013 Aug; 108(2):337-41. PubMed ID: 24074814
[TBL] [Abstract][Full Text] [Related]
12. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy.
Kwint M; Uyterlinde W; Nijkamp J; Chen C; de Bois J; Sonke JJ; van den Heuvel M; Knegjens J; van Herk M; Belderbos J
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e223-8. PubMed ID: 22560551
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy.
Hayashi K; Fujiwara Y; Nomura M; Kamata M; Kojima H; Kohzai M; Sumita K; Tanigawa N
Br J Radiol; 2015 Feb; 88(1046):20140168. PubMed ID: 25429644
[TBL] [Abstract][Full Text] [Related]
14. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
15. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
16. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
[TBL] [Abstract][Full Text] [Related]
17. Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
Iocolano M; Yegya-Raman N; Friedes C; Wang X; Kegelman T; Lee SH; Duan L; Li B; Levin WP; Cengel KA; Konski A; Langer CJ; Cohen RB; Sun L; Aggarwal C; Doucette A; Xiao Y; Kevin Teo BK; O'Reilly S; Zou W; Bradley JD; Simone CB; Feigenberg SJ
Cancer; 2024 Jun; 130(11):2031-2041. PubMed ID: 38294959
[TBL] [Abstract][Full Text] [Related]
18. Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.
Eaton BR; Pugh SL; Bradley JD; Masters G; Kavadi VS; Narayan S; Nedzi L; Robinson C; Wynn RB; Koprowski C; Johnson DW; Meng J; Curran WJ
J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27206636
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
20. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
Liao Z; Lee JJ; Komaki R; Gomez DR; O'Reilly MS; Fossella FV; Blumenschein GR; Heymach JV; Vaporciyan AA; Swisher SG; Allen PK; Choi NC; DeLaney TF; Hahn SM; Cox JD; Lu CS; Mohan R
J Clin Oncol; 2018 Jun; 36(18):1813-1822. PubMed ID: 29293386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
